Summary of Haemonetics Conference Call Company Overview - **Company**: Haemonetics - **Industry**: Medical Technology (MedTech) - **Revenue**: Approaching $1.4 billion, diversified small midcap MedTech company - **Market Leadership**: Global leader in plasma apheresis with a billion-dollar addressable market [2][3] Key Financial Performance - **Fiscal Year Performance**: - High single-digit revenue growth - Operating margin expansion of over 800 basis points - Cumulative free cash flow of $600 million to $700 million - Added $3 in earnings per share over the four-year long-range plan (LRP) [3] Plasma Business Insights - **Growth**: Plasma segment grew 3% organically, 20% excluding CSL [4] - **Drivers of Growth**: - Sustained share gains - Innovation-led platform benefits - Increased collection strength [5] - **Persona PLUS Launch**: - Mid-single digit yield increase compared to Persona - Built on data-driven approach with a pivotal trial involving over 30,000 plasma donations [6][8] Customer Relationships and Market Position - **Customer Engagement**: Strong relationships leading to share gains and deeper strategic partnerships [10] - **Market Leadership**: Expectation to grow global marketplace leadership for the foreseeable future [12] Competitive Landscape - **Competitors**: Mention of Terumo's Rika and other competitors, with emphasis on Haemonetics' integrated platform and lower cost metrics [13][14] - **NexSys and Persona PLUS**: Positive reception from customers, leading to standardization around Haemonetics' technology [10] Interventional Technologies and Vascular Closure - **Challenges**: Acknowledgment of challenges in the vascular closure space but confidence in returning to above-market growth [19][20] - **Market Dynamics**: Shift to Ambulatory Surgical Centers (ASCs) and increased adoption of PFA expected to favor Haemonetics [21] - **Product Launches**: - MVP label expansion in the U.S. and Japan - Vivasure acquisition leading to the launch of PerQseal Elite [21][27] Blood Management Technologies - **Growth Potential**: Blood management technologies, particularly TEG, showing consistent double-digit growth with significant market penetration opportunities [33][34] - **Market Size**: Global Serviceable Available Market (SAM) for TEG estimated at over $400 million, with less than 50% penetration [34] Capital Deployment Strategy - **Focus on Organic Growth**: Prioritizing R&D and commercial execution for competitive advantage [43] - **Debt Management**: Addressed $300 million debt maturity using revolver, maintaining capital structure efficiency [44] - **Share Repurchases**: Attractive risk-adjusted returns at current share prices, with plans for opportunistic capital deployment [44] Margin Improvement - **Current Margins**: Operating income margin increased from 13% to 26% over the past decade, with aspirations for further improvement [48][49] - **Future Expectations**: Anticipation of continued margin expansion driven by operational improvements and product mix [49] Outlook for FY27 - **Growth Expectations**: Balanced, sustainable growth with continued revenue growth, margin expansion, and free cash flow [53] Conclusion - **Company's Position**: Haemonetics is positioned for future growth with a strong focus on innovation, customer relationships, and market leadership in plasma and blood management technologies [55]

Financial Data and Key Metrics Changes - Third quarter revenue was $339 million, bringing year-to-date revenue to $988 million, with reported revenue reflecting a $153 million impact from last year's portfolio transitions [4][10] - Adjusted earnings per share increased 10% in the quarter to $1.31 and 11% year-to-date to $3.67, indicating strong earnings quality and durability [5][14] - Adjusted gross margin was 60.2% in the third quarter, up 250 basis points year-over-year, driven by the adoption of NexSys technology and divestiture of the Whole Blood business [11][12] - Free cash flow for the third quarter was $74 million, with year-to-date free cash flow reaching $165 million, representing a threefold increase compared to the prior year [15][16] Business Line Data and Key Metrics Changes - Hospital revenue was $144 million in the third quarter, down 1% but up 2% year-to-date organically, with blood management technologies growing 8% in the quarter [5][6] - Plasma revenue was $139 million, up 3% on a reported basis, with organic growth of 20% in the quarter, driven by share gains and collection volume [8][9] - Blood Center revenue was $57 million in the quarter, growing 3% organically, primarily due to international plasma demand [9][10] Market Data and Key Metrics Changes - U.S. plasma collections grew in the low double digits in the third quarter, with the company holding approximately 50% global market share [8][9] - The hospital business is expected to deliver reported and organic growth of approximately 4% at the low end of the prior 4%-7% range [7][10] Company Strategy and Development Direction - The company is focused on returning the Interventional Technologies franchise to sustainable growth in fiscal 2027, with targeted actions underway to strengthen this segment [18][19] - The Vivisure acquisition is expected to enhance the company's leadership in vascular closure, with a market opportunity estimated at $300 million [44][47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the plasma business, highlighting strong relationships and a favorable market environment [24][26] - The company anticipates continued margin expansion and strong cash flow generation, with a focus on disciplined capital deployment [15][21] Other Important Information - Adjusted operating income increased 4% year-to-date to $254 million, with adjusted operating margin expanding 200 basis points to 25.7% [13][14] - The company raised its full-year revenue guidance to a decline of 1%-3%, reflecting improved performance across Plasma, Blood Center, and Blood Management Technologies [10][11] Q&A Session Summary Question: Can you provide insights on plasma collections and market growth? - Management indicated that share gains and collection volume are driving growth, with double-digit increases in both U.S. and international collections [24][25] Question: What are the expectations for margins moving forward? - Management expects smaller increments in margin improvements in the future, with ongoing focus on operational efficiency [29][30] Question: What is the status of the IVT business and competition? - Management noted that 70% of the decline in IVT was due to specific market disruptions, but they are confident in returning to growth with the right strategies in place [35][36] Question: Can you elaborate on the Vivisure acquisition and its market potential? - The acquisition is seen as a significant opportunity to enhance the company's position in vascular closure, with a focus on a stepwise approach to market entry [44][47] Question: How is the company addressing the challenges in the hospital business? - Management highlighted strong performance in blood management technologies and a focus on stabilizing the IVT segment as key to future growth [81][82]

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were $44 million, representing a 17% increase year over year from $37.7 million in Q1 2024 [4][11] - Adjusted EBITDA for Q1 2025 was $11.6 million, up approximately 54% from $7.5 million in Q1 2024 [4][13] - Net income increased to $4 million or $0.07 per share, a 67% rise from $2.4 million or $0.04 per share in Q1 2024 [13] Business Line Data and Key Metrics Changes - Growth was primarily driven by increased sales of Glacia and Kamrab in ex-U.S. markets, as well as Varezig sales and Glacier royalties income [5][11] - Gross profit for Q1 2025 was $20.7 million with a gross margin of 47%, compared to $16.7 million and 44% in Q1 2024 [12] Market Data and Key Metrics Changes - The company expanded its plasma collection operation with a new center in San Antonio, Texas, which is expected to contribute annual revenues of $8 million to $10 million [9][10] - The company is active in over 35 countries, enhancing its global market presence [19] Company Strategy and Development Direction - The company is focused on a four-pillar growth strategy: organic commercial growth, business development and M&A, plasma collection operations, and advancing the Phase III inhaled Alpha-one program [6][40] - The company plans to launch two additional biosimilars later this year, with expectations of generating $15 million to $20 million in annual sales from this portfolio within the next five years [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued profitable growth throughout 2025, reiterating annual revenue guidance of $178 million to $182 million and adjusted EBITDA of $38 million to $42 million [5][6] - Management noted that the initiation of a comprehensive post-marketing research program for Cytogam aims to demonstrate its advantages in CMV disease management [7][8] Other Important Information - The company is currently at around 55% enrollment for the pivotal Phase III INNO2VATE clinical trial for inhaled alpha-one antitrypsin therapy [26] - The company maintains a strong cash position to fund new business development initiatives [13] Q&A Session Summary Question: Growth contributors for Cytogam - Management clarified that while Cytogam is a growth contributor, the significant growth this quarter came from other products, emphasizing the strength and diversity of their portfolio [16][18] Question: Impact of tariffs on global business - Management indicated that there should be no direct impact on sales from current tariff discussions, but they will continue to monitor the situation [22][24] Question: Timing of Cytogam post-marketing study completion - Management stated that the comprehensive program consists of multiple studies with varying timelines, some results expected as early as late 2025 and others extending to 2028 [30] Question: Impact of NIH spending cutbacks - Management does not anticipate any impact on the business from NIH spending cutbacks due to the unique nature of their products [31][32] Question: Tax rate changes - Management explained that the increase in tax rate is due to changes in fair tax liability, with no cash effect, and they expect to start paying taxes by the end of 2025 or early 2026 [33][34]

Group 1: Company Performance - In Q1 2025, the company reported a revenue of 2.006 billion, a decrease of 2.45% year-on-year, and a net profit of 566 million, down 25.20% year-on-year [5] - The company’s revenue in 2024 was 8.176 billion, with a year-on-year growth of 2.67%, and a net profit of 2.193 billion, an increase of 23.25% [17] - The company’s inventory as of March 31, 2025, was 4.12 billion, primarily consisting of raw materials and finished goods [4] Group 2: Market Dynamics - The blood product industry is experiencing stable demand, with human albumin in a balanced state and immunoglobulin in a tight balance [2] - The pricing of blood products is influenced by supply-demand relationships and healthcare policies, with expectations of continued rigid demand in the future [3][11] Group 3: Research and Development - The company is focusing on key R&D projects, including SR604, which is currently in Phase II clinical trials [4] - The company has initiated R&D on products like protein C and activated prothrombin complex, which have not yet entered clinical trials [2] Group 4: Strategic Initiatives - The company is pursuing a dual strategy of "expanding plasma collection" and "innovative drug development" to enhance its market position [21] - The company plans to utilize a share buyback program, with a total budget of 250 million to 500 million RMB, to boost investor confidence [23] Group 5: Financial Management - The company has implemented measures to enhance shareholder returns, including stock buybacks and cash dividends [24] - The company’s financial leverage and asset efficiency will be optimized to improve its return on equity (ROE) [26]